Antibodies recognizing alpha-synuclein

Patent metadata

Field	Value
Publication number	US-9605056-B2
Application number	US-201314049169-A
Country	US
Kind code	B2
Filing date	Oct 8, 2013
Priority date	Oct 8, 2012
Publication date	Mar 28, 2017
Grant date	Mar 28, 2017

Abstract

The invention provides monoclonal antibody 5C1 and related antibodies. The 5C1 antibody binds to an epitope within residues 118-126 of α-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with α-synuclein, particularly accumulation of α-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA).

First claim

What is claimed is:

1. An isolated monoclonal antibody that binds to a human alpha synuclein at an epitope consisting of residues 120-124 of SEQ ID NO: 1, wherein alanine mutagenesis of the human alpha synuclein at any of residues 118, 119, 125 and 126 does not change binding of the antibody.

2. The antibody of claim 1 wherein the antibody is at least 95% w/w pure.

3. A pharmaceutical composition comprising an antibody as defined in claim 1 and a pharmaceutically-acceptable carrier.

4. The antibody of claim 1 , wherein the antibody is chimeric, veneered or humanized.

5. An isolated monoclonal antibody, comprising three light chain CDRs as defined by Kabat and three heavy chain CDRs as defined by Kabat of monoclonal antibody 5C1, wherein 5C1 is a mouse antibody characterized by a heavy chain variable region having an amino acid sequence comprising SEQ ID NO: 9 and light chain variable region having an amino acid sequence comprising SEQ ID NO: 24.

6. The antibody of claim 5 that is an Fab fragment, or single chain Fv.

7. The antibody of claim 5 , wherein the isotype is human IgG1.

8. The antibody of claim 5 having at least one mutation in the constant region, wherein the mutation reduces complement fixation or activation by the constant region.

9. The antibody of claim 8 having a mutation at one or more of positions 241, 264, 265, 270, 296, 297, 322, 329 and 331 by EU numbering.

10. The antibody of claim 5 comprising a mature heavy chain variable region having an amino acid sequence at least 90% identical to SEQ ID NO: 17 and a mature light chain variable region having an amino acid sequence at least 90% identical to SEQ ID NO: 31, wherein the antibody specifically binds to human alpha synuclein.

11. The antibody of claim 10 , provided at least one of positions H11, H27, H30, H48, and H73 is occupied by L, Y, T, I, and K, respectively, and at least one of positions L12 and L14 is occupied by S.

12. The antibody of claim 11 , provided positions H11, H27, H30, H48, and H73 are occupied by L, Y, T, I, and K, respectively, and positions L12 and L14 are occupied by S.

13. The antibody of claim 11 , provided at least one of positions H67, H69, and H94 is occupied by A, L, and S, respectively.

14. The antibody of claim 13 , provided positions H67, H69, and H94 are occupied by A, L, and S, respectively.

15. The antibody of claim 13 , provided position H94 is occupied by S.

16. The antibody of claim 11 , provided at least one of the positions L2, L49, and L87 is occupied by V, N, and F, respectively.

17. The antibody of claim 16 , provided positions L2, L49, and L87 are occupied by V, N, and F, respectively.

18. The antibody of claim 11 , wherein the mature heavy chain variable region is fused to a heavy chain constant region and the mature light chain variable region is fused to a light chain constant region.

19. The antibody of claim 18 , wherein the mature heavy chain variable region is fused to a heavy chain constant region having the sequence of SEQ ID NO: 38 and/or the mature light chain variable region is fused to a light chain constant region having the sequence of SEQ ID NO: 40.

20. The antibody of claim 10 , wherein the mature heavy chain variable region has an amino acid sequence designated SEQ ID NO: 17 and the mature light chain variable region has an amino acid sequence designated SEQ ID NO: 31.

21. An isolated monoclonal antibody, wherein the mature heavy chain variable region has an amino acid sequence designated SEQ ID NO: 18 and the mature light chain variable region has an amino acid sequence designated SEQ ID NO: 31.

22. The antibody of claim 10 , wherein the antibody is a Fab fragment.

Assignees

• Prothena Biosciences Ltd

Inventors

• Barbour Robin
• Games Thiel Kate Dora
• Nijjar Tarlochan S

Classifications

• A61P25/16

  Anti-Parkinson drugs · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/14

  for treating abnormal movements, e.g. chorea, dyskinesia · CPC title

• A61P25/20

  Hypnotics; Sedatives · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title